• Bionano Genomics Inc BNGO.OQ BNGO.O is expected to show a fall in quarterly revenue when it reports results on November 13 for the period ending September 30 2024

• The San Diego California-based company is expected to report a 15.7% decrease in revenue to $7.854 million from $9.32 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.The company's guidance on October 10 2024, for the period ended September 30, was for revenue between $6.50 million and $6.80 million.

• ​LSEG's mean analyst estimate for Bionano Genomics Inc is for a loss of 21 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Bionano Genomics Inc is $1.90​, above​ its last closing price of $0.28. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated November 12 at 03:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)